Our study showed as follows; accompanied with insulin, switching from DPP-4 inhibitors to dapagliflozin maintained an equivalent glucose fluctuation and all-day and nocturnal hypoglycaemia prevalence without significant insulin dosage change. Here, DPP4 is linked to Hypoglycemia.